Are you curious about cancer immunotherapy everyone in the oncology world is talking about? Do you love using and advancing your skills to analyze complex data and shedding light on current research questions?
Apply until Nov 30, 2020 / Xplorers Camp on Dec 4, 2020
What is the impact of former CPI-treatment on patients participating in Roche Immunotherapy trials?
Checkpoint inhibitor (CPI)-based immunotherapies that target the CTLA4 or PD1/PD-L1 pathway have achieved impressive success in the treatment of different cancer types. The number of patients with cancer who receive immune checkpoint-based therapies is rapidly increasing following a growing number of approved indications. Testing novel cancer immunotherapies in early clinical Phase 1 studies face the situation that most of the patients today have been exposed to those CPI-based immunotherapies. Understanding the impact of previous exposure to CPI-based immunotherapies is important to recruit the “right” patients for testing novel cancer immunotherapies in early clinical Phase 1 studies. Little is known about the impact of past CPI-treatment on a patient’s response to novel cancer immunotherapies. Clinical as well as biomarker data of enrolled patients from early clinical Phase 1 studies have been integrated into a large virtual cohort to identify features of those patients with the goal to improve the current patient selection strategies.
Dr. Franziska Braun
Senior Data Scientist
Preferred scale: 6-12 months full-time (flexible models are also possible)
Possible format: Internship
Show us how you would approach the problem. You can prepare your idea proposal in 3-5 slides, any other idea/format to share your proposal with us is also welcome. We do not expect a bullet-proof solution to the problem.
Specific skills we will check during the Xplorer Camp:
By sending this to us via the submit button you agree to the following: